Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure

Benjamin French, Le Wang, Bonnie Ky, Jeffrey Brandimarto, Anupam Basuray, James C. Fang, Nancy K Sweitzer, Thomas P. Cappola

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Background: Clinical studies have suggested the prognostic value of galectin-3, a marker of fibrosis, in chronic heart failure. However, the specific role of galectin-3, compared with established biomarkers, remains uncertain. Methods and Results: The Penn Heart Failure Study was an ambulatory heart failure cohort that included 1385 participants with reduced (1141), preserved (106), and recovered (138) left ventricular ejection fraction (LVEF). Cox regression models determined the association between galectin-3 and risk of all-cause mortality, cardiac transplantation, or placement of a ventricular assist device. Receiver operating characteristic curves compared the prognostic accuracy of galectin-3, high-sensitivity soluble Toll-like receptor 2 (ST2), troponin I, and B-type natriuretic peptide (BNP) at 1 and 5 years. Higher galectin-3 levels were associated with an increased risk of adverse events (adjusted hazard ratio of 1.96 for each doubling in galectin-3; P <.001). This association was most pronounced among participants with preserved LVEF (adjusted hazard ratio 3.30; P <.001). At 5 years, galectin-3 was the most accurate discriminator of risk among participants with preserved LVEF (area under the curve 0.782; P = .81 vs high-sensitivity ST2; P = .029 vs troponin I; P = .35 vs BNP). BNP was most accurate among participants with reduced and recovered LVEF (areas under the curves 0.716 and 0.728, respectively). Conclusions: Galectin-3 could have prognostic value for long-term events among patients with heart failure and preserved ejection fraction.

Original languageEnglish (US)
JournalJournal of Cardiac Failure
DOIs
StateAccepted/In press - May 21 2015

Keywords

  • Biomarker
  • Ejection fraction
  • Risk stratification
  • Ventricular function

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure'. Together they form a unique fingerprint.

  • Cite this

    French, B., Wang, L., Ky, B., Brandimarto, J., Basuray, A., Fang, J. C., Sweitzer, N. K., & Cappola, T. P. (Accepted/In press). Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2015.10.022